American Society of Hematology

Figure 1.

$PFS of relapsed/refractory TFH vs non-TFH phenotype PTCL after HDACi. PFS was 4.1 months for TFH phenotype patients and 2.1 months for non-TFH phenotype patients; log rank P = .18 (HR 0.5 for TFH; 95% CI, 0.33-0.75). For patients undergoing allogeneic stem cell transplantation, time on the curve was censored at the time of transplant.$

PFS of relapsed/refractory TFH vs non-TFH phenotype PTCL after HDACi. PFS was 4.1 months for TFH phenotype patients and 2.1 months for non-TFH phenotype patients; log rank P = .18 (HR 0.5 for TFH; 95% CI, 0.33-0.75). For patients undergoing allogeneic stem cell transplantation, time on the curve was censored at the time of transplant.

This Feature Is Available To Subscribers Only